权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

The Impact of Maternal CMV Infection on Birth Outcomes

母亲巨细胞病毒感染对出生结果的影响

基本信息

批准号：
10331331
负责人：
Raymond Preston Stowe
金额：
$ 8.95万
依托单位：
MICROGEN, LLC
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-01-22 至 2023-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10331331
关键词：
Address Affect Affinity Antibodies Avidity Binding Biological Assay Birth Blindness Blood Blood Tests Blood Volume Child Congenital Abnormality Counseling Cytomegalovirus DNA Data Detection Development Developmental Disabilities Diagnosis Enrollment Enzyme-Linked Immunosorbent Assay Epidemic Equipment Fingers Funding Future Goals Human Immune System Diseases Immunoglobulin G Immunoglobulin M Infant Infection Inflammation Infrastructure Laboratories Lateral Life Live Birth Longitudinal Studies Maternal antibody Measures Mediating Methods Motor Newborn Infant Outcome Patients Peptides Performance Predictive Value Pregnancy Pregnancy Outcome Pregnant Women Primary Infection Process Prospective Studies Proteins Protocols documentation Rapid screening Risk Saliva Salivary Sampling Sensitivity and Specificity Sensory Serum Signal Transduction Site Spottings Techniques Testing Time Training UNICEF Urea Viral Viral Antibodies Viral Load result Virus Diseases Visit Visualization Whole Blood Woman Work ZIKA congenital cytomegalovirus congenital infection data tools design disability hearing impairment immune function indexing infant infection infant outcome lateral flow assay neonatal outcome neonate novel outcome prediction point of care testing polypeptide prevent rapid test risk stratification screening seroconversion transmission process vaccine evaluation

项目摘要

Congenital Cytomegalovirus (CMV) infection is a leading cause of birth defects and developmental disabilities in the U.S., affecting thousands of children each year. Notably, the majority of children acquire congenital CMV from non-primary maternal CMV infection rather than primary infection. Thus, determining the maternal serostatus in the field may further our understanding of the association between CMV infection status and worse pregnancy outcome, and risk stratify pregnant women during gestation. Current methods to detect maternal CMV serostatus are labor intensive and require sophisticated equipment, dedicated laboratory space, and trained technicians. We propose developing a point-of-care (POC) test for rapid screening of maternal CMV serostatus. A rapid, on-site test for CMV serostatus screening in biospecimens would: (1) allow for immediate counseling and confirmatory testing, and (2) avoid having to create new laboratory infrastructure for biospecimen testing. Alternatively, a rapid POC test that could be utilized during initial study screening visits would permit the efficient identification and enrollment for CMV vaccine testing.

在美国，先天性巨细胞病毒(CMV)感染是导致出生缺陷和发育障碍的主要原因，每年影响成千上万的儿童。值得注意的是，大多数儿童先天性巨细胞病毒是通过非原发母体巨细胞病毒感染而不是原发感染感染的。因此，现场检测孕妇血清状况可能会进一步了解CMV感染状况与不良妊娠结局之间的关系，并对怀孕期间的孕妇进行危险分层。目前检测母体巨细胞病毒血清状况的方法是劳动密集型的，需要复杂的设备、专用的实验室空间和训练有素的技术人员。我们建议开发一种用于快速筛查母亲CMV血清状态的护理点(POC)检测方法。生物检疫中CMV血清学筛查的现场快速检测将：(1)允许立即进行咨询和确证测试，以及(2)避免为生物检疫检测创建新的实验室基础设施。或者，可以在最初的研究筛查访问期间使用的快速POC测试将允许有效地识别和登记CMV疫苗测试。